CL2017001904A1 - Composición para el tratamiento de enfermedad veno-oclusiva hepática. - Google Patents

Composición para el tratamiento de enfermedad veno-oclusiva hepática.

Info

Publication number
CL2017001904A1
CL2017001904A1 CL2017001904A CL2017001904A CL2017001904A1 CL 2017001904 A1 CL2017001904 A1 CL 2017001904A1 CL 2017001904 A CL2017001904 A CL 2017001904A CL 2017001904 A CL2017001904 A CL 2017001904A CL 2017001904 A1 CL2017001904 A1 CL 2017001904A1
Authority
CL
Chile
Prior art keywords
treatment
composition
occlusive disease
hepatic veno
vivid
Prior art date
Application number
CL2017001904A
Other languages
English (en)
Inventor
Michael Freissmuth
Eva-Maria Zebedin-Brandl
Zahra Kazemi
Christoph Österreicher
Ursula Lemberger
Madeleine Themanns
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of CL2017001904A1 publication Critical patent/CL2017001904A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UNA COMPOSICIÓN QUE COMPRENDE UN ANÁLOGO DE PROSTACICLINA, DERIVADO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, PARA EL USO EN PREVENIR O TRATAR EL SÍNDROME DE OBSTRUCCIÓN SINUSOIDAL Y/O ENFERMEDAD VENO-OCLUSIVA HEPÁTICA (VOD) ASÍ COMO REGÍMENES DE TRATAMIENTO DE LOS MISMOS.</p>
CL2017001904A 2015-01-27 2017-07-25 Composición para el tratamiento de enfermedad veno-oclusiva hepática. CL2017001904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15152665 2015-01-27

Publications (1)

Publication Number Publication Date
CL2017001904A1 true CL2017001904A1 (es) 2018-03-23

Family

ID=52394992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001904A CL2017001904A1 (es) 2015-01-27 2017-07-25 Composición para el tratamiento de enfermedad veno-oclusiva hepática.

Country Status (14)

Country Link
US (1) US20180021347A1 (es)
EP (1) EP3250289A1 (es)
JP (1) JP2018503654A (es)
KR (1) KR20170106360A (es)
CN (1) CN107592811A (es)
AU (1) AU2016212091A1 (es)
BR (1) BR112017016084A2 (es)
CA (1) CA2973147A1 (es)
CL (1) CL2017001904A1 (es)
EA (1) EA201791696A1 (es)
IL (1) IL253390A0 (es)
SG (1) SG11201705809QA (es)
WO (1) WO2016120311A1 (es)
ZA (1) ZA201704957B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427609B2 (en) 2017-12-14 2022-08-30 Aop Orphan Ip Ag Glycosidic derivatives of treprostinil

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2020154585A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427609B2 (en) 2017-12-14 2022-08-30 Aop Orphan Ip Ag Glycosidic derivatives of treprostinil

Also Published As

Publication number Publication date
AU2016212091A1 (en) 2017-08-03
CA2973147A1 (en) 2016-08-04
US20180021347A1 (en) 2018-01-25
ZA201704957B (en) 2018-12-19
KR20170106360A (ko) 2017-09-20
JP2018503654A (ja) 2018-02-08
WO2016120311A1 (en) 2016-08-04
IL253390A0 (en) 2017-09-28
EA201791696A1 (ru) 2017-11-30
CN107592811A (zh) 2018-01-16
EP3250289A1 (en) 2017-12-06
BR112017016084A2 (pt) 2018-03-27
SG11201705809QA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CL2016002971A1 (es) Combinación.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX378904B (es) Vacunas para virus influenza y usos de las mismas.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015002897A1 (es) Inhibidores de bace1
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени